Genmab — December 2025
-
After Genmab (GMAB) announced it will discontinue further clinical development of acasunlimab, Guggenheim calls this “a good decision by management” given that the firm had no value reflected in its model and estimates for acasunlimab based on low conviction in the probability of success of this candidate.
-
Det her må være den sidste poster fra ESMO i december ? https://oncologypro.esmo.org/congress-resources/esmo-immuno-oncology-congress-2025?presentation=acasunlimab_monotherapy_or_with_pembrolizumab_in_c
-
Genmab shelves Phase III lung cancer candidate https://www.pharmaceutical-technology.com/news/genmab-shelves-phase-iii-lung-cancer-candidate/?cf-view
-
https://ir.merus.nl/node/12296/html Merus acquisition completed if i understand it correctly, all shares with Genmab now. Trading in Merus halted / delisted
-
Godmorgen og godt nyt år til at alle.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind